Drug intelligence / Profile preview

MIC8411

Development stage: Preclinical
Lead developer: Micar Innovation
Modality: Small Molecules

Overview

MIC8411 is a small molecule therapeutic candidate being developed by Micar Innovation for the treatment of melasma. Melasma is a common skin condition characterized by dark, discolored patches on the skin, typically on the face. As of the current pipeline information, MIC8411 is in the preclinical stage of development. While the specific biological target for MIC8411 has not been publicly disclosed by the developer, it is part of Micar Innovation's portfolio of small molecule drugs discovered using their proprietary drug discovery platform.

Beyond the preview

Go deeper on MIC8411.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIC8411.

Explore the full profile